DEFA14A: Mural Oncology Mails Proxy for XOMA Royalty Acquisition

Mural Oncology plc has commenced mailing its definitive proxy statement to shareholders regarding the acquisition by XOMA Royalty Corporation via a scheme of arrangement.

Summary

• Mural Oncology plc has published and commenced mailing its definitive proxy statement, which also constitutes a scheme circular under Irish law, to Mural shareholders.
• XOMA Royalty Corporation, through its wholly-owned subsidiary XRA 5 Corp., has agreed to acquire the entire issued and to be issued share capital of Mural via an Irish High Court sanctioned scheme of arrangement.
• The proxy statement contains important information about the acquisition, including full terms and conditions, voting instructions, and details of actions to be taken by Mural shareholders.
• Holders of Mural equity awards have been sent a proposal describing the treatment of their awards in the acquisition.
• A Scheme Meeting for Mural shareholders to consider and vote on the Scheme will be held on October 24, 2025, at 10:30 a.m. Irish local time.
• An Extraordinary General Meeting (EGM) will follow the Scheme Meeting on October 24, 2025, at 10:45 a.m. Irish local time.
• Both meetings will be held at Ten Earlsfort Terrace, Dublin 2, D02 T380, Ireland.
• Mural previously announced on March 25, 2025, that its Phase 3 ARTISTRY-7 trial of nemvaleukin alfa failed to achieve its primary endpoint, leading to the cessation of development for platinum-resistant ovarian cancer.
• On April 15, 2025, Mural announced the discontinuation of all clinical development of nemvaleukin and initiated an exploration of strategic alternatives to maximize shareholder value.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company faced significant setbacks with clinical trial failures, the announcement of the proxy mailing for the acquisition by XOMA Royalty provides a clear, albeit likely low-value, exit strategy for shareholders, preventing further capital burn on failed programs. It represents a resolution to a negative situation.

Positives

• A definitive transaction agreement has been reached for the acquisition of Mural Oncology by XOMA Royalty Corporation, providing a clear path forward after significant clinical setbacks.
• The acquisition represents a strategic alternative focused on maximizing shareholder value following the discontinuation of all clinical development programs.

Negatives

• The Phase 3 ARTISTRY-7 trial of nemvaleukin alfa in combination with pembrolizumab did not achieve its primary endpoint of a statistically significant improvement in overall survival for platinum-resistant ovarian cancer.
• Mural ceased development of nemvaleukin for platinum-resistant ovarian cancer.
• All clinical development of nemvaleukin was discontinued following a review of data from the Phase 2 ARTISTRY-6 trial and the ARTISTRY-7 trial results.

Risks

• Uncertainties exist regarding the timing and completion of the Scheme Meeting and Extraordinary General Meeting.
• There are uncertainties as to the approval by Mural's shareholders of the required resolutions at both the Scheme Meeting and the EGM.
• The possibility remains that closing conditions for the Acquisition may not be satisfied or waived, including the failure to receive sanction of the Scheme by the Irish High Court.
• Ongoing costs to Mural could result in the company's actual closing net cash on the Closing Net Cash Calculation Date not exceeding the Estimated Closing Net Cash, which would mean no Additional Price Per Share is paid to Mural shareholders.
• Other risks and uncertainties pertaining to Mural's business, including those described in its most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and subsequent SEC filings, including the Proxy Statement.
• Potential risks and uncertainties related to XOMA Royalty, including those described in its most recent Quarterly Report on Form 10-Q and other SEC filings.

Future Outlook

Mural Oncology and XOMA Royalty Corporation intend to consummate the acquisition, subject to approval by Mural's shareholders at the Scheme Meeting and EGM, and sanction by the Irish High Court. The payment of any Additional Price Per Share to Mural shareholders is contingent on Mural's actual closing net cash exceeding the estimated closing net cash.

Management Comments

• The members of the Mural Board of Directors accept responsibility for the information contained in this announcement.

Industry Context

This announcement reflects a common trend in the biotechnology industry where companies facing significant clinical trial failures seek strategic alternatives, often leading to acquisitions or mergers. It underscores the high-risk nature of drug development, where late-stage trial failures can necessitate a pivot to preserve shareholder value. XOMA Royalty's acquisition of a company with discontinued clinical programs suggests a strategic interest in the remaining assets or intellectual property, or a broader portfolio adjustment.

Corporate Governance

Stakeholder Impact

• Shareholders: Will vote on the acquisition and, if approved, will receive consideration for their shares, potentially including an Additional Price Per Share if net cash conditions are met.
• Equity Award Holders: Have been sent a proposal describing the treatment of their equity awards in the acquisition.
• Employees: While not explicitly stated, the discontinuation of all clinical development and subsequent acquisition typically leads to significant changes in employment, potentially including layoffs or integration into the acquiring company.

Next Steps

• Mural shareholders are urged to thoroughly read the definitive proxy statement and other relevant documents filed with the SEC.
• Mural shareholders are to attend and vote on the Scheme of Arrangement at the Scheme Meeting on October 24, 2025.
• Mural shareholders are to attend and vote on related matters at the Extraordinary General Meeting on October 24, 2025.
• The acquisition will proceed to completion, subject to shareholder approval and sanction by the Irish High Court.

Key Dates

Recommendation

The filing details the procedural steps for an already announced acquisition following significant clinical trial failures. While the acquisition provides an exit, the value is likely capped, and the company's core drug development programs have been discontinued. Investors should hold to realize the acquisition value, but there is no new information to suggest a 'buy' or 'sell' beyond the previously announced strategic pivot.

Keywords

Mural Oncology, XOMA Royalty, Acquisition, Scheme of Arrangement, Proxy Statement, Immuno-oncology, Clinical Trials, Nemvaleukin, ARTISTRY-7, ARTISTRY-6, Ovarian Cancer, Melanoma, Biotechnology, SEC Filing, Corporate Governance, M&A